Angiogenesis and lung cancer;Angiogenèse et cancer bronchique

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Pérol, Maurice ^a   Arpin, Dominique ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Angiogenesis; Lung cancer; Targeted therapy

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AE 788; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; HYPOXIA INDUCIBLE FACTOR 1; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ARTERY THROMBOSIS; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIGESTIVE SYSTEM HEMORRHAGE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; NECROSIS; NEUTROPENIA; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; METALLOPROTEASES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548605828     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0349     Document Type: Review

References (60)

1. Molinié F, Velten M, Remontet L, Bercelli P, Reseau Francim. Évolution de l'incidence du cancer broncho-pulmonaire en France (1978-2000). Rev Mal Respir 2006 ; 23 : 127-34.
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003 ; 3 : 401-10.
3. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer : towards marker and target identification. Nat Rev Cancer 2006 ; 6 : 835-45.
4. Sardari Nia P, Colpaert C, Blyweert B, et al. Prognostic value of nonangiogenic and angiogenic growth patterns in non-small-cell lung cancer. Br J Cancer 2004 ; 91 : 1293-300.
5. Bikfalvi A. Angiogenèse tumorale. Bull Cancer 2006 ; 93 : 154-64.
6. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer : a systematic review of the literature with meta-analysis. Br J Cancer 2002 ; 87 : 694-701.
7. Delmotte P, Martin B, Paesmans M, et al. VEGF and survival of patients with lung cancer : a systematic literature review and meta-analysis. Rev Mal Respir 2002 ; 19 : 577-84.
8. Nakashima T, Huang CL, Liu D, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit 2004 ; 10 : BR157-BR165.
9. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer : the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006 ; 51 : 143-58.
10. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000 ; 82 : 1427-32.
11. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer : prognostic and therapeutic implications. J Clin Oncol 2005 ; 23 : 3243-56.
12. Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S. Current status and perspective of angiogenesis and antivascular therapeutic strategy : non-small cell lung cancer. Int J Clin Oncol 2006 ; 11 : 73-81.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 ; 23 : 1011-27.
14. Nilsson M, Heymach JV. Vascular endothelial growth factor pathway. J Thorac Oncol 2006 ; 1 : 768-70.
15. Midgley R, Kerr D. Bevacizumab: current status and future directions. Ann Oncol 2005 ; 16 : 999-1004.
16. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 2184-91.
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
18. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171 : a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005 ; 65 : 4389-400.
19. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005 ; 23 : 3002.
20. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006 ; 24 : 7002.
21. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. J Clin Oncol 2006 ; 24 : 7001.
22. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer. Ann Oncol 2006 ; 17 : 729.
23. Gauler TC, Fischer B, Soria JC, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients with stage IIIB or stage IV non-small cell lung cancer. J Clin Oncol 2006 ; 24 : 7195.
24. Besse B, Gauler TC, Fischer B, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily or twice daily at 1250 mg as second-line monotherapy in patients with stage IIIB ot stage IV non-small cell lung cancer. Ann Oncol 2006 ; 17 : 730.
25. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002 ; 62 : 2554-60.
26. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005 ; 16 : 1391-7.
27. Minami H, Ebi H, Tahara M, et al. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003 ; 22 (abstr. 778).
28. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus géfitinib in patients with advanced NSCLC : final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006 ; 24 : 7000.
29. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC : follow-up results. J Clin Oncol 2006 ; 24 : 7016.
30. Sridhar SS, Shepherd FA. Targeting angiogenesis : a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003 ; 42 : S81-91.
31. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002 ; 20 : 4434-9.
32. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001 ; 20 (abstr. 1226).
33. Bissett D, von Pawel J, Mercier R, et al. Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002 ; 21 (abstr. 1183).
34. Leighl NB, Shepherd F, Paz-Ares L, et al. Randomized phase II-III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer : NCIC-CTG BR.18. J Clin Oncol 2004 ; 22(14S) : 7038.
35. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001 ; 28 : 620-5.
36. Herbst RS, Madden TL, Tran HT, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors : evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002 ; 20 : 4440-7.
37. Herbst RS, Hammond LA, Carbone DP, et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003 ; 9 : 4108-15.
38. Eble JA, Haier J. Integrins in cancer treatment. Curr Cancer Drug Targets 2006 ; 6 : 89-105.
39. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994 ; 91 : 4082-5.
40. Pujol JL, Breton JL, Gervais K, et al. A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease SCLC patients after response to chemotherapy : an intergroup study FNCLCC Cleo04 - IFCT 00-01. J Clin Oncol 2006 ; 24(18S) : 7057.
41. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004 ; 10 : 415-27.
42. Goto H, Yano S, Zhang H, et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002 ; 62 : 3711-5.
43. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006 ; 24 : 1491-8.
44. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 ; 353 : 123-32.
45. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006 ; 3 : 24-40.
46. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003 ; 63 : 4342-6.
47. Socinski MA, Schell MJ, Bakri K, et al. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV non-small cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer 2002 ; 95 : 1265-73.
48. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 ; 22 : 1589-97.
49. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidetmal growth factor receptor tyrosine kinase inhibitor etlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 2544-55.
50. Fehrenbacher L, O'Neill VO, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent ot refractory non-small cell lung cancer. J Clin Oncol 2006 ; 24 : 7062.
51. Wedge SR, Kendrew J, Olgivie DJ, et al. Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res 2002 ; 43 : A5351.
52. Jung S, Moon KS, Jung TY, et al. Possible pathophysiological role of vascular endothelial growth factor and matrix metalloproteinases in metastatic brain tumor-associated intracerebral hemorrhage. J Neurooncol 2006 ; 76 : 257-63.
53. Sandler AB, Johnson DH, Brahmer J, et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer. J Clin Oncol 2006 ; 24 : 7068.
54. Dowlati A, Gray R, Johnson DH, Schiller JH, Brahmer J, Sandler AB. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer. J Clin Oncol 2006 ; 24 : 7027.
55. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001 ; 12 : 987-90.
56. Collins JM. Imaging and other biomarkers in early clinical studies : one step at a time or re-engineering drug development? J Clin Oncol 2005 ; 23 : 5417-9.
57. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis : applications and potential for drug development. J Natl Cancer Inst 2005 ; 97 : 172-87.
58. Guo J, Higashi K, Ueda Y, Oguchi M, et al. Microvessel density : correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med 2006 ; 47 : 419-25.
59. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006 ; 24 : 3299-308.
60. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F] galacto-RGD. PLoS Med 2005 ; 2 : e70.